GLP-1 Market
LLY $1351.12 ▼ -2.3% NVO $38.87 ▼ -1.4% PFE $27.54 ▼ -1.9% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $58.99 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Efsubaglutide Alfa

Company
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 20, 2026

Find a Clinical Trial Near Me

See recruiting studies for Efsubaglutide Alfa and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07163650

    Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery

    Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 60 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Obesity, Weight Loss, Metabolic Surgery
    View official trial listing →
  • Recruiting NCT NCT07693426

    Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 36 participants Est. completion 2027-08-31 5 sites Stand-alone
    Other conditions: Adolescence Obesity
    View official trial listing →
  • Completed NCT NCT06732960

    A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 50 participants Est. completion 2024-11-18 3 sites Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06849843

    A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients.

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 59 participants Est. completion 2025-05-29 10 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT06900075

    Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 88 participants Est. completion 2026-03-31 Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06921486

    The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

    Not yet reported, Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 1003 participants Est. completion 2026-12-31 41 sites Stand-alone
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Completed NCT NCT07114419

    The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 200 participants Est. completion 2026-07-06 5 sites Stand-alone
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Not yet recruiting NCT NCT07518121

    A Bridging Study of Efsubaglutide Alfa in Healthy Adults in Brazil

    Not yet reported Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. 48 participants Est. completion 2026-10-31 1 site Stand-alone
    Other conditions: Diabete Type 2
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Efsubaglutide Alfa, Efsubaglutide Alfa 20 mg QW, Efsubaglutide Alfa 40 mg QW, Efsubaglutide Alfa 80 mg QW

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.